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Abstract
Purpose—Investigate associations between maternal use of common medications and herbals 
during early pregnancy and risk for hypospadias in male infants.
Methods—We used data from the National Birth Defects Prevention Study, a multi-site, 
population-based, case-control study. We analyzed data from 1,537 infants with second-or third-
degree isolated hypospadias and 4,314 liveborn male control infants without major birth defects, 
with estimated dates of delivery from 1997–2007. Exposure was reported use of prescription or 
over-the-counter medications or herbal products, from 1 month before to 4 months after 
conception. Adjusted odds ratios (aORs) and 95% confidence intervals (CI) were estimated using 
multivariable logistic regression, adjusting for maternal age, race/ethnicity, education, pre-
pregnancy BMI, previous live births, maternal sub-fertility, study site, and year.
Results—We assessed 64 medication and 24 herbal components. Maternal uses of most 
components were not associated with an increased risk of hypospadias. Two new associations 
were observed for venlafaxine (aOR 2.4; 95% CI 1.0, 6.0) and progestin only oral contraceptives 
(aOR 1.9, 95% CI 1.1, 3.2). The previously reported association for clomiphene citrate was 
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confirmed (aOR 1.9, 95% CI 1.2, 3.0). Numbers were relatively small for exposure to other 
specific patterns of fertility agents, but elevated aORs were observed for the most common of 
them.
Conclusions—Overall, findings were reassuring that hypospadias is not associated with most 
medication components examined in this analysis. New associations will need to be confirmed in 
other studies. Increased risks for hypospadias associated with various fertility agents raises the 
possibility of confounding by underlying subfertility.
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INTRODUCTION
Medication use is highly prevalent among pregnant women, despite the fact that few data 
exist on risks or safety of most medications.1–5 In the United States, more than 80% of 
pregnant women reported taking over-the-counter (OTC) or prescription drugs during 
pregnancy,3,6 and the overall prevalence of herbal use anytime during pregnancy was 
recently estimated at 9.4%.7 While medications can be necessary during pregnancy, they can 
pose a potential risk to both mother and fetus. Pregnancy is associated with physiologic and 
pharmacokinetic changes that potentially alter the dosing, effectiveness, and ultimately, the 
safety of many drugs.4
Hypospadias, one of the most common birth defects in the United States (~5/1,000 live male 
births8), is a birth defect in male infants in which the urethral opening forms abnormally 
during weeks 8 to 14 following conception. Degrees of hypospadias range from minor (first 
degree) to severe (second or third degree). Hypospadias has been associated with a wide 
range of endocrine, genetic, and environmental factors (e.g. androgen metabolism 
abnormalities, chromosome abnormalities, single gene mutations, family history of 
hypospadias, low birth weight, maternal reproductive and demographic characteristics, 
maternal and paternal sub-fertility, and exposure to endocrine disruptors).9,10 In addition, 
use of certain medications in pregnancy has been observed to be associated with risk for 
hypospadias in previous studies.11–14
The objective of this study was to conduct an exploratory analysis to assess associations 
between maternal use of common medication components and certain combinations, 
including prescription, over-the-counter, and herbal preparations, during the 
periconceptional period and early pregnancy and the risk for second- or third-degree 
hypospadias in male infants.
METHODS
Study Population and Data Collection
The National Birth Defects Prevention Study (NBDPS) is an ongoing, multi-site, 
population-based, case-control study coordinated by the Centers for Disease Control and 
Prevention (CDC) that seeks to identify risk factors associated with more than 30 selected 
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categories of major birth defects. Data have been contributed by 10 states (Arkansas, 
California, Georgia, Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, 
and Utah), using a standardized protocol. The study was approved by the institutional review 
boards of the participating study centers and by CDC, and participants provided informed 
consent. Detailed study methods15 and description of case classification methods16 have 
been published elsewhere.
NBDPS uses computer-assisted telephone interviews to collect information from women 6 
weeks to 24 months after their estimated date of delivery (EDD). The interview covers a 
wide range of exposures including maternal health and reproductive characteristics, 
environmental exposures, and nutritional and behavioral factors.
NBDPS cases are identified through population-based birth defects surveillance. Controls 
are selected randomly from vital records or birth logs to represent the population from which 
the birth defects cases were ascertained. NBDPS includes infants with second- or third-
degree hypospadias, defined as the urethral opening at the penile shaft, scrotum, or perineum 
and including modified versions of British Pediatric Association codes: 752.606, 752.607, 
752.626, and 752.627; NBDPS excludes first-degree hypospadias. A clinical geneticist 
classifies eligible cases of hypospadias as isolated, if there was no concurrent major 
anomaly or only minor anomalies, or multiple, if there was at least one unrelated 
accompanying major anomaly in another organ system.16
This analysis included data on pregnancies with EDDs from October 1, 1997-December 31, 
2007. The analysis was restricted to male infants with no major birth defects (controls) and 
male infants with isolated second- or third-degree hypospadias; isolated cases represented 
90.6% of all hypospadias cases and are considered a more etiologically homogeneous group 
of defects than those associated with additional anomalies.16–19 We defined exposure as any 
maternal medication or herbal use from 1 month (30 days) before to 4 months after 
conception (defined as 266 days before the estimated due date), to capture the period of 
development for the male urogenital system.10 We did not require that the medication or 
herbal components be taken in isolation, and co-exposures were possible and in many cases 
likely. Because oral contraceptives (OC) and fertility treatments often comprise 
combinations of components, these combinations were considered rather than the individual 
components. Due to the way in which mothers were asked about OC, we were only able to 
consider these exposures through 3 months postconception. The Slone Epidemiology Center 
Drug Dictionary was used to assign codes for each reported product and to identify the 
components of each product. We assessed only medication or herbal components for which 
at least a minimum of one of the salts of the component had 5 exposed mothers of infants 
with isolated hypospadias. All salt forms for components with multiple salts were then 
combined. Topicals, vitamins, and minerals were not included in this analysis. If a multi-
component product contained topical, vitamin, or mineral components, only the medication 
or herbal components were considered.
Statistical Analysis
Crude odds ratios (ORs) and adjusted odds ratios (aORs) and 95% confidence intervals (CIs) 
were estimated using unconditional logistic regression. We selected a priori the following 
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covariates to adjust for potential confounding: maternal age (<35/≥35 yr), race/ethnicity 
(Non-Hispanic White/Non-Hispanic Black/Hispanic/Other), education (<high school/high 
school/1–3 yr of college/≥4 yr of college), pre-pregnancy body mass index (BMI) 
(<18.5/18.5–24.9/25.0–29.9/≥30.0 kg/m2),20 previous live births (0 births/1 birth/≥2 births), 
maternal sub-fertility (any fertility-related treatments or procedures used by the mother/
none), study site, and year of due date in two year increments. Fertility agent analyses were 
not adjusted for maternal sub-fertility, except for progesterone use alone because the 
majority of reports were for pregnancy complications. Two sub-analyses were performed on 
elevated crude or adjusted ORs with a lower 95% CI ≥0.95 and on reduced crude or adjusted 
ORs with a corresponding upper bound ≤1.05 in the primary analyses (i.e. at least borderline 
statistically significant). The first sub-analysis excluded infants with a positive first degree 
family history of hypospadias (father, full sibling, or previous pregnancy), due to the 
increased risk for hypospadias in first-degree male relatives.10,21,22 Also, given the 
hypothesis that placental insufficiency is associated with both fetal growth and hypospadias, 
the second sub-analysis excluded low birth weight infants and multiple births, as done in 
some previous analyses.12,23–25 Data management and analysis were performed using the 
Statistical Package for the Social Sciences (SPSS) software, version 17.0.
RESULTS
There were 1,697 infants with second- or third-degree hypospadias with an EDD from 
October 1997 to December 2007 in NBDPS. Of these infants, 1,537 (90.6%) had isolated 
hypospadias. The control group consisted of 4,314 male infants with no major birth defects. 
One hundred and ninety-six medication or herbal components were identified for which at 
least one of the salts of the component had 5 exposed cases. Of the 196 medication or herbal 
components, 109 topicals, vitamins, and minerals were excluded. Thus, 88 components (64 
from medication, including 4 combinations, and 24 from herbal products) were assessed for 
their association with hypospadias.
Comparing the case and control groups, there were many significant differences in maternal 
and infant characteristics (Table 1). Mothers of infants with isolated hypospadias were 
significantly more likely than control mothers to be Non-Hispanic White, 35 years of age or 
older at delivery, have 4 or more years of college, be obese, have pregestational diabetes, 
have a higher annual family income, have used alcohol during the periconceptional period, 
have used folic acid during the periconceptional period, be nulliparous, have given birth to 
multiples, and have used treatments or procedures for sub-fertility. Control mothers were 
significantly more likely than case mothers to be Hispanic and have used illicit drugs during 
the periconceptional period. Case infants were significantly more likely than control infants 
to be delivered preterm, have a low birth weight, and have a family history of hypospadias. 
There were also differences in the distribution of isolated hypospadias cases and controls by 
study site and EDD.
After adjusting for maternal age, race/ethnicity, education, pre-pregnancy BMI, previous 
live births, maternal sub-fertility, study site, and year of due date, most medication and 
herbal components were not associated with a risk for isolated hypospadias (Table 2). Of the 
seven analgesic agents examined, aORs were greater than 1.0 for uses of aspirin, meperidine 
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HCl, and ibuprofen, but only the aOR for ibuprofen was statistically significant (aOR 1.2; 
95% CI 1.0, 1.3). Of the five antidepressant agents examined, aORs were close to 1.0 for all 
but venlafaxine (aOR 2.4; 95% CI 1.0, 6.0). Use of the most common OC, estrogen
+progestin, was not associated with hypospadias, whereas use of progestin alone was 
associated with a nearly twofold increased risk (aOR 1.9; 95% CI 1.1, 3.2). There were 28 
different combinations of six fertility agents (clomiphene citrate (CLO), follicle stimulating 
hormone (FSH), human chorionic gonadotropin (HCG), leuprolide (LEU), progesterone 
(PRO), and estrogen); six of them were reported frequently enough to estimate aORs. Use of 
clomiphene citrate alone and FSH+HCG+LEU+PRO were associated with hypospadias; 
aORs (and 95% CIs) were 1.9 (1.2, 3.0) and 2.2 (1.0, 4.8), respectively.
Of the 83 medication and herbal components and five component combinations considered 
in the primary analyses, 18 (acetaminophen, aspirin, azithromycin, barley grass, butalbital, 
progesterone alone, clomiphene citrate alone, FSH+HCG+LEU+PRO, CLO+PRO, FSH
+HCG+PRO, FSH+PRO, herbal tea, ibuprofen, labetalol, levothyroxine sodium, 
phenylpropanolamine, progestin-only OC, and venlafaxine) had at least borderline 
statistically significant crude or adjusted OR estimates for their association with isolated 
hypospadias. Overall, sub-analyses in which infants with a positive first degree family 
history of hypospadias were excluded did not change aOR estimates appreciably (Table 3). 
Sub-analyses in which low birth weight infants and multiple births were excluded 
demonstrated results closer to the null relative to the primary analysis for several of the 
medication components (Table 4), particularly clomiphene citrate (aOR 1.6; 95% CI 0.9, 
2.9) and progestin-only OCs. However, in this sub-analysis, the magnitude of the association 
of isolated hypospadias was much larger for maternal use of venlafaxine (aOR 3.7; 95% CI 
1.4, 9.7).
DISCUSSION
The results of this analysis suggest an association between second- or third-degree 
hypospadias and maternal use during the period of 1 month before to 4 months after 
conception of ibuprofen, venlafaxine, progestin-only OC, clomiphene citrate alone, and FSH
+HCG+LEU+PRO. While findings for the fertility medications are consistent with other 
studies,26,27 the progestin-only OC and venlafaxine findings are novel and should be 
explored in other data sources.
Although only a weak statistically significant association was observed for ibuprofen, future 
studies could investigate this association because it is a common medication. Ibuprofen is a 
non-steroidal anti-inflammatory drug (NSAID) that works by decreasing the activity of the 
enzyme cyclooxygenase (COX), resulting in the inhibition of prostaglandin synthesis.28 
Animal models suggest that the action of testosterone on embryonic genitalia involves 
prostaglandins and that prenatal exposure to COX inhibitors inhibits masculinization of male 
genitalia.29 In another study utilizing NBDPS data from 1997–2004,30 NSAID use during 
the first trimester and the risk of birth defects was evaluated; no association was observed 
for 2nd and 3rd degree hypospadias. There were, however, fewer cases classified as exposed 
to ibuprofen in that study (n=99) compared to this one (n=423), due to their shorter 
exposure window, the separation of women who could not characterize the frequency of 
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NSAID use in the first trimester into a separate “as needed” category, and different 
exclusion criteria. Excluding the “as needed” exposures from our data did not substantially 
affect our findings. Our observation of an elevated odds ratio for maternal use of ibuprofen, 
although statistically significant, is close to the null and, therefore, minor bias or 
misclassification of exposure could account for the observed slightly increased odds ratio. 
Although statistically significant, ibuprofen is a more common medication and therefore has 
higher power (i.e. a modest departure from the null is more likely to be statistically 
significant).
With the exception of progesterone alone, elevated aORs were observed for the five most 
common patterns of fertility agent exposures, but numbers were small and lower 95% CIs 
included 1.0 for all but one. The elevated ORs for exposure to different patterns of fertility 
agents may be confounded by underlying subfertility, which we were unable to evaluate 
because these agents are rarely taken for other indications. Subfertility, both maternal and 
paternal, has been proposed to contribute to a higher risk for hypospadias.31, 32 In previous 
analyses of NBDPS data, hypospadias was similarly associated with maternal use of 
clomiphene citrate alone 27 and use of assisted reproductive technologies overall, but further 
refinement of fertility agent exposures were not examined.33 An earlier subset of NBDPS 
data showed no association for progestin exposure from OCs.12 That study did not separate 
OCs comprised of estrogen and progestin from those comprised of progestin alone; the latter 
formulations were less popular during those years, and their null finding likely corresponds 
to the present null finding for estrogen/progestin combination OCs. That same study also 
reported an approximately two-fold increased OR for progesterone taken for sub-fertility or 
pregnancy complications for women with and without exposure to other fertility agents. In 
contrast, the OR in the present study was not elevated for progesterone taken without other 
fertility agents, but ORs were elevated for the five most common combinations of 
progesterone and other fertility agents.
Another consideration for fertility medications and risk of hypospadias is the possible role 
for fetal growth, multiple births, and placental insufficiency. Ovulation induction 
medications are associated with an increased risk for multiple births.34–37 An increased 
prevalence of hypospadias has been previously observed in both monozygotic and dizygotic 
twins.21 After excluding low birth weight infants and multiple births, ORs were generally 
similar to those for the primary analysis, suggesting that any effect of these exposures on 
hypospadias risk is through another pathway than one shared with fetal growth or multiple 
gestations.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used in the treatment of 
depression and anxiety.28 Serotonin and norepinephrine play a role in embryologic signaling 
pathways, and it is therefore plausible that a medication that interacts with these 
neurotransmitters may affect embryogenesis.29–30 Despite evidence that there is substantial 
transfer of venlafaxine across the placenta,40 there are few published reports describing its 
use during pregnancy.41 No association was observed in two small case series (N<40).42–43 
A study by Einarson and colleagues reported that among 150 women exposed to venlafaxine 
during pregnancy, two babies were born with major malformations, of which one had 
hypospadias; drug-specific ORs were not estimated.42 None of these studies was sufficiently 
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powered to detect an association of the magnitude we observed here (aOR = 2.4; 95% CI = 
1.0, 6.0). A recently-published NBDPS analysis reported an association between 
hypospadias and any periconceptional exposure to venlafaxine, but this association did not 
remain when concurrent medications were excluded 43.
Several analyses using NBDPS data have been published on the association of a specific 
medication or herbal and hypospadias. The findings in this analysis are consistent with 
several other studies in which no significant association between risk for hypospadias and 
exposure to loratadine,44 certain antibiotics,45 certain SSRIs,46 ephedra,47 certain 
antihistamines,48 acetaminophen,49 bupropion,50 certain opioid analgesics,51 certain 
corticosteroids,23 or certain antihypertensives50 were observed. Our results are also 
consistent with the positive association reported for hypospadias and proton pump 
inhibitors, which included lansoprazole and ompeprazole.11 We examined each agent 
separately, producing greater than 2.8-fold increased aORs with lower 95% CIs that 
included 1.0.
This study had several strengths. The data came from a large, population-based study that 
allowed for sufficient statistical power to analyze numerous medication and herbal 
exposures during the critical period for male urethral development. The multi-center study 
design provided geographic diversity. There was consistent and detailed case ascertainment, 
with cases reviewed and classified by clinical geneticists, allowing for exclusion of defects 
with genetic etiologies and restriction to isolated hypospadias cases.
The study has several limitations. Maternal medication and herbal use was not exclusive and 
mothers may have been using multiple medications or herbals concurrently. Many of the 
medication and herbal exposures were in multiple component products; however the 
analysis was on the component level, not combined product level other than for fertility 
agents and some OCs, for which nearly all use is in a combination. Furthermore, 
confounding by indication is a potential limitation, due to our inability to separate effects of 
the underlying conditions from those of the medications used. Inability to examine dose of 
medications or herbals is a limitation. While overall this was a large study, there were a 
small number of exposed infants for some medication and herbal components, which could 
affect the robustness of results. Medication and herbal exposures were determined by 
maternal report; hence exposure misclassification is another potential limitation of the study. 
To improve recall, NBDPS mothers were provided with a pregnancy calendar before the 
interview to help them respond to questions about the timing of exposure more accurately. 
Some medications and herbals were specifically queried, while others were reported as 
treatment for reported maternal medical conditions. With 88 different medication and herbal 
components and combinations examined in this analysis, another limitation is multiple 
testing. Given the exploratory nature of the analyses, the aim of these results is to help 
generate hypotheses for future analyses. Also, there are still many medications and herbals 
that were not evaluated and these results therefore cannot be used to make generalized 
statements about the overall risk of maternal medication and herbal use on hypospadias. In 
addition, there were some substantial differences in rates of second -degree hypospadias by 
study site. Definitive descriptions of the type of hypospadias were often not available at the 
time of initial case ascertainment. The extent of clinical follow-up information from 
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providers and referral hospitals was variable across study sites, therefore infants whose type 
of hypospadias was not specified were excluded from NBDPS more frequently at some 
sites. We attempted to address the differences in hypospadias ascertainment by adjusting for 
study site in the analyses. A sub-analysis in which the study sites were stratified into two 
groups, high ascertainment and lower ascertainment, resulted in numbers too small to 
interpret any differences. Finally, because the study population was limited to infants with 
isolated second- or third-degree hypospadias it was not possible to examine potential 
associations between specific medication or herbal exposures and milder forms of 
hypospadias.
In conclusion, most of the medication and herbal components examined in this analysis were 
not associated with an increased risk for isolated second- or third-degree hypospadias in 
male infants, with the exception of progestin-only OCs, clomiphene citrate alone, FSH
+HCG+LEU+PRO, ibuprofen, and venlafaxine. Future studies on the associations observed 
here, on combinations of medications not assessed in this analysis, and on medications and 
herbals not included in this study are warranted. Further investigation into medications and 
herbals associated with a risk for hypospadias will allow clinicians and women of 
childbearing age to make more informed decisions regarding clinical management of 
maternal conditions.
Acknowledgments
• This work was supported through cooperative agreements under PA 96043, PA 02081 and FOA 
DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects 
Research and Prevention participating in the National Birth Defects Prevention Study.
• We thank the California Department of Public Health Maternal Child and Adolescent Health Division 
for providing data for these analyses. The findings and conclusions in this report are those of the authors 
and do not necessarily represent the views of the California Department of Public Health.
References
1. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: 
ignorance not bliss. Clin Pharmacol Ther. 2008; 83(1):181–3.10.1038/sj.clpt.6100448 [PubMed: 
18073777] 
2. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine 
use in a rural, obstetric population. Am J Obstet Gynecol. 2003; 188(4):1039–45.10.1067/mob.
2003.223 [PubMed: 12712107] 
3. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. National Birth 
Defects Prevention S. Medication use during pregnancy, with particular focus on prescription drugs: 
1976–2008. Am J Obstet Gynecol. 2011; 205(1):51, e1–8.10.1016/j.ajog.2011.02.029 [PubMed: 
21514558] 
4. Refuerzo JS, Blackwell SC, Sokol RJ, Lajeunesse L, Firchau K, Kruger M, Sorokin Y. Use of over-
the-counter medications and herbal remedies in pregnancy. Am J Perinatol. 2005; 22(6):321–
4.10.1055/s-2005-873235 [PubMed: 16118721] 
5. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications 
during pregnancy. Am J Obstet Gynecol. 2005; 193(3 Pt 1):771–7.10.1016/j.ajog.2005.02.100 
[PubMed: 16150273] 
6. Black RA, Hill DA. Over-the-counter medications in pregnancy. Am Fam Physician. 2003; 67(12):
2517–24. [PubMed: 12825840] 
Lind et al. Page 8













7. Broussard CS, Louik C, Honein MA, Mitchell AA. National Birth Defects Prevention S. Herbal use 
before and during pregnancy. Am J Obstet Gynecol. 2010; 202(5):443, e1–6.10.1016/j.ajog.
2009.10.865 [PubMed: 20035911] 
8. Paulozzi LJ, Erickson JD, Jackson RJ. Hypospadias trends in two US surveillance systems. 
Pediatrics. 1997; 100(5):831–4.10.1542/peds.100.5.831 [PubMed: 9346983] 
9. Carmichael SL, Shaw GM, Lammer EJ. Environmental and genetic contributors to hypospadias: a 
review of the epidemiologic evidence. Birth Defects Res A Clin Mol Teratol. 2012; 94(7):499–
510.10.1002/bdra.23021 [PubMed: 22678668] 
10. Stokowski LA. Hypospadias in the neonate. Adv Neonatal Care. 2004; 4(4):206–15.10.1016/
j.adnc.2004.05.003 [PubMed: 15368213] 
11. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA. National 
Birth Defects Prevention S. Medications used to treat nausea and vomiting of pregnancy and the 
risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012; 94(1):22–30.10.1002/
bdra.22865 [PubMed: 22102545] 
12. Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin 
intake and risk of hypospadias. Arch Pediatr Adolesc Med. 2005; 159(10):957–62.10.1001/
archpedi.159.10.957 [PubMed: 16203941] 
13. Czeizel AE, Kazy Z, Puho E. A population-based case-control teratological study of oral nystatin 
treatment during pregnancy. Scand J Infect Dis. 2003; 35(11–12):830–
5.10.1080/00365540310017069 [PubMed: 14723358] 
14. Rodriguez-Pinilla E, Mejias C, Prieto-Merino D, Fernandez P, Martinez-Frias ML, Group EW. 
Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of 
pregnancy: a case-control study in Spain. Drug Saf. 2008; 31(6):537–
43.10.2165/00002018-200831060-00008 [PubMed: 18484787] 
15. Yoon PW, Rasmussen SA, Lynberg MC, Moore CA, Anderka M, Carmichael SL, Costa P, 
Druschel C, Hobbs CA, Romitti PA, Langlois PH, Edmonds LD. The National Birth Defects 
Prevention Study. Public Health Rep. 2001; 116 (Suppl 1):32–40.10.1093/phr/116.S1.32 
[PubMed: 11889273] 
16. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. National Birth 
Defects Prevention S. Guidelines for case classification for the National Birth Defects Prevention 
Study. Birth Defects Res A Clin Mol Teratol. 2003; 67(3):193–201.10.1002/bdra.10012 [PubMed: 
12797461] 
17. Friedman JM. The use of dysmorphology in birth defects epidemiology. Teratology. 1992; 45(2):
187–93.10.1002/tera.1420450212 [PubMed: 1615428] 
18. Khoury MJ, James LM, Flanders WD, Erickson JD. Interpretation of recurring weak associations 
obtained from epidemiologic studies of suspected human teratogens. Teratology. 1992; 46(1):69–
77.10.1002/tera.1420460110 [PubMed: 1641813] 
19. Khoury MJ, Moore CA, James LM, Cordero JF. The interaction between dysmorphology and 
epidemiology: methodologic issues of lumping and splitting. Teratology. 1992; 45(2):133–
8.10.1002/tera.1420450206 [PubMed: 1615423] 
20. National Heart L, and Blood Institute. Clinical guidelines on the identification, evaluation, and 
treatment of overweight and obesity in adults. National Institutes of Health; 1998. Vol. NIH 
Publication No. 98–4083
21. Fredell L, Kockum I, Hansson E, Holmner S, Lundquist L, Lackgren G, Pedersen J, Stenberg A, 
Westbacke G, Nordenskjold A. Heredity of hypospadias and the significance of low birth weight. J 
Urol. 2002; 167(3):1423–7.10.1016/S0022-5347(05)65334-7 [PubMed: 11832761] 
22. Schnack TH, Zdravkovic S, Myrup C, Westergaard T, Christensen K, Wohlfahrt J, Melbye M. 
Familial aggregation of hypospadias: a cohort study. Am J Epidemiol. 2008; 167(3):251–
6.10.1093/aje/kwm317 [PubMed: 18042671] 
23. Carmichael SL, Ma C, Werler MM, Olney RS, Shaw GM. National Birth Defects Prevention S. 
Maternal corticosteroid use and hypospadias. J Pediatr. 2009; 155(1):39–44. 44 e1.10.1016/j.jpeds.
2009.01.039 [PubMed: 19394038] 
Lind et al. Page 9













24. Fredell L, Lichtenstein P, Pedersen NL, Svensson J, Nordenskjold A. Hypospadias is related to 
birth weight in discordant monozygotic twins. J Urol. 1998; 160(6 Pt 1):2197–9.10.1016/
S0022-5347(01)62294-8 [PubMed: 9817368] 
25. Main KM, Jensen RB, Asklund C, Hoi-Hansen CE, Skakkebaek NE. Low birth weight and male 
reproductive function. Horm Res. 2006; 65 (Suppl 3):116–22.10.1159/000091516 [PubMed: 
16612124] 
26. Meijer WM, de Jong-Van den Ber LT, van den Ber MD, Verheij JB, de Walle HE. Clomiphene 
and hypospadias on a detailed level: singal or chance? Birth Defects Res A Clin Mol Teratol. 
2006; 76(4):249–52.10.1002/bdra.20243 [PubMed: 16586447] 
27. Reefhuis J, Honein MA, Schieve LA, Rasmussen SA. National Birth Defects Prevention S. Use of 
clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997–2005. Hum 
Reprod. 2011; 26(2):451–7.10.1093/humrep/deq313 [PubMed: 21112952] 
28. Lacy, CF.; Armstrong, LL.; Goldman, MP. Drug Information Handbook: 2006–2007. 14. Lexi-
Comp; 2006. 
29. Lauder JM. Neurotransmitters as morphogens. Prog Brain Res. 1988; 73:365–387. [PubMed: 
2901778] 
30. Buznikov GA, Lambert HW, Lauder JM. Serotonin and serotonin-like substances as regulatores of 
early embryogenesis and morphogenesis. Cell Tissue Res. 2001; 305:177–186. [PubMed: 
11545255] 
31. Gupta C, Goldman AS. The arachidonic acid cascade is involved in the masculinizing action of 
testosterone on embryonic external genitalia in mice. Proc Natl Acad Sci U S A. 1986; 83(12):
4346–9.10.1073/pnas.83.12.4346 [PubMed: 3086881] 
32. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. National Birth Defects Prevention S. 
Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet 
Gynecol. 2012; 206(3):228, e1–8.10.1016/j.ajog.2011.11.019 [PubMed: 22196851] 
33. Baskin LS. Hypospadias. Adv Exp Med Biol. 2004; 545:3–22.10.1007/978-1-4419-8995-6_1 
[PubMed: 15086017] 
34. Carmichael SL, Shaw GM, Laurent C, Olney RS, Lammer EJ. National Birth Defects Prevention 
S. Maternal reproductive and demographic characteristics as risk factors for hypospadias. Paediatr 
Perinat Epidemiol. 2007; 21(3):210–8.10.1111/j.1365-3016.2007.00809.x [PubMed: 17439529] 
35. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA. National Birth Defects 
Prevention S. Assisted reproductive technology and major structural birth defects in the United 
States. Hum Reprod. 2009; 24(2):360–6.10.1093/humrep/den387 [PubMed: 19010807] 
36. Corchia C, Mastroiacovo P, Lanni R, Mannazzu R, Curro V, Fabris C. What proportion of multiple 
births are due to ovulation induction? A register-based study in Italy. Am J Public Health. 1996; 
86(6):851–4.10.2105/AJPH.86.6.851 [PubMed: 8659661] 
37. Kallen B, Olausson PO, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. 
Obstet Gynecol. 2002; 100(3):414–9.10.1016/S0029-7844(02)02069-0 [PubMed: 12220758] 
38. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum 
Reprod Update. 1997; 3(4):359–65.10.1093/humupd/3.4.359 [PubMed: 9459281] 
39. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod 
Biomed Online. 2002; 4(3):303–10.10.1016/S1472-6483(10)61821-4 [PubMed: 12709286] 
40. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Forman 
T. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. 
Pharmacopsychiatry. 2009; 42(3):95–100.10.1055/S-0028-1103296 [PubMed: 19452377] 
41. Briggs, GG.; Freeman, RK.; Yaffe, SJ. Drugs in Pregnancy and Lactation. Lippincott Williams & 
Wilkins; 2001. 
42. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo P, Addis A, 
Matsui D, Schuler L, Einarson TR, Koren G. Pregnancy outcome following gestational exposure 
to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001; 158(10):1728–
30.10.1176/appi.ajp.158.10.1728 [PubMed: 11579012] 
43. Polen K, Rasmussen SA, Colarusso T, Reefhuis J. The association between reported venlafaxine 
use in early pregnancy and birth defects, National Birth Defects Prevention Study, 1997–2007. 
Lind et al. Page 10













Birth Defects Res A Clin Mol Teratol. 2013; 97(1):28–35.10.1002/bdra.23096 [PubMed: 
23281074] 
44. Werler M, McCloskey C, Edmonds LD, Olney RS, Honein MA, Reefhuis J. Evaluation of an 
Association Between Loratadine and Hypospadias --- United States, 1997--2001. MMWR Morb 
Mortal Wkly Rep. 2004; 53(10):219–221.10.1001/jama.291.15.1828 [PubMed: 15029117] 
45. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use 
during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr 
Adolesc Med. 2009; 163(11):978–85.10.1001/archpediatrics.2009.188 [PubMed: 19884587] 
46. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. National Birth Defects Prevention 
S. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl 
J Med. 2007; 356(26):2684–92.10.1056/NEJMoa066584 [PubMed: 17596602] 
47. Bitsko RH, Reefhuis J, Louik C, Werler M, Feldkamp ML, Waller DK, Frias J, Honein MA. 
National Birth Defects Prevention S. Periconceptional use of weight loss products including 
ephedra and the association with birth defects. Birth Defects Res A Clin Mol Teratol. 2008; 82(8):
553–62.10.1002/bdra.20472 [PubMed: 18553492] 
48. Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A. National Birth Defects Prevention 
S. Use of antihistamine medications during early pregnancy and isolated major malformations. 
Birth Defects Res A Clin Mol Teratol. 2009; 85(2):137–50.10.1002/bdra.20513 [PubMed: 
19161158] 
49. Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth 
defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol. 2010; 115(1):
109–15.10.1097/AOG.0b013e3181c52616 [PubMed: 20027042] 
50. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM. National Birth Defects 
Prevention S. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet 
Gynecol. 2010; 203(1):52, e1–6.10.1016/j.ajog.2010.02.015 [PubMed: 20417496] 
51. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, Honein 
MA. National Birth Defects Prevention S. Maternal treatment with opioid analgesics and risk for 
birth defects. Am J Obstet Gynecol. 2011; 204(4):314, e1–11.10.1016/j.ajog.2010.12.039 
[PubMed: 21345403] 
52. Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, McNutt LA, Romitti 
PA, Olney RS, Correa A. National Birth Defects Prevention S. Maternal hypertension, 
antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol 
Teratol. 2008; 82(1):34–40.10.1002/bdra.20415 [PubMed: 18022875] 
Lind et al. Page 11














• Most of the medication and herbal components examined in this analysis were 
not associated with an increased risk for second- or third-degree hypospadias in 
male infants after adjustment for appropriate confounders.
• Future studies on the associations observed here, between subfertility and its 
treatments, progestin-only oral contraceptives, and venlafaxine during the 
periconceptional period and an increased risk for second- or third-degree 
hypospadias in male infants, are warranted.
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Table 1
Descriptive Characteristics of Mothers of Infants with Isolated Second- and Third-Degree Hypospadias (cases) 
and Male Infants with No Major Birth Defects (controls): National Birth Defects Prevention Study, October 
1997 to December 2007
Maternal Characteristic Cases (n= 1537) Controls (n= 4314) P Valuea
N (%)
Race/Ethnicity < .001
 Non-Hispanic White 1,125 (73.2%) 2,513 (58.3%)
 Non-Hispanic Black 194 (12.6%) 479 (11.1%)
 Hispanic 122 (7.9%) 1,019 (23.6%)
 Other 95 (6.2%) 301 (7.0%)
Age at Delivery < .001
 <35 yr 1,224 (79.6%) 3,721 (86.3%)
 ≥35 yr 313 (20.4%) 593 (13.7%)
Education < .001
 < High School 117 (7.6%) 756 (17.5%)
 High School 295 (19.2%) 1,047 (24.3%)
 1–3 yr of College 420 (27.3%) 1,125 (26.1%)
 ≥4 yr of College 680 (44.2%) 1,309 (30.3%)
Pre-pregnancy Body Mass Index (kg/m2) .003
 Underweight (<18.5) 80 (5.2%) 238 (5.5%)
 Normal (18.5–24.9) 824 (53.6%) 2,272 (52.7%)
 Overweight (25.0–29.9) 341 (22.2%) 938 (21.7%)
 Obese (≥30.0) 257 (16.7%) 674 (15.6%)
Pregestational Diabetes .03
 Yes 16 (1.0%) 22 (0.5%)
 No 1411 (91.8%) 3983 (92.3%)
Annual Family Income < .001
 <$10,000 149 (9.7%) 793 (18.4%)
 $10,000–$50,000 533 (34.7%) 1764 (40.9%)
 >$50,000 756 (49.2%) 1324 (30.7%)
Cigarette Smokingb .42
 Yes 265 (17.2%) 809 (18.8%)
 No 1248 (81.2%) 3,441 (79.8%)
Alcohol Useb < .001
 Yes 656 (42.7%) 1583 (36.7%)
 No 847 (55.1%) 2644 (61.3%)
Maternal Illicit Drug Useb .02
 Yes 50 (3.3%) 202 (4.7%)
 No 1487 (96.7%) 4,112 (95.3%)
Folic Acid-Containing Supplement Usec .002
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Maternal Characteristic Cases (n= 1537) Controls (n= 4314) P Valuea
 Yes 1,400 (91.1%) 3,813 (88.4%)
 No 129 (8.4%) 485 (11.2%)
Previous Live Births < .001
 0 births 816 (53.1%) 1,729 (40.1%)
 1 birth 454 (29.5%) 1,419 (32.9%)
 ≥2 births 260 (16.9%) 1,157 (26.8%)
Plurality < .001
 Singleton 1,416 (92.1%) 4,182 (96.9%)
 Multiple 119 (7.7%) 123 (2.9%)
Maternal Subfertility Treatments and Procedures < .001
 None 1,373 (89.3%) 4,121 (95.5%)
 Any 157 (10.2%) 180 (4.2%)
Study Site < .001
 Arkansas 209 (13.6%) 539 (12.5%)
 California 68 (4.4%) 523 (12.1%)
 Georgia 212 (13.8%) 459 (10.6%)
 Iowa 84 (5.5%) 473 (11.0%)
 Massachusetts 335 (21.8%) 534 (12.4%)
 New Jersey 286 (18.6%) 258 (6.0%)
 New York 92 (6.0%) 383 (8.9%)
 North Carolina 124 (8.1%) 312 (7.2%)
 Texas 28 (1.8%) 530 (12.3%)
 Utah 99 (6.4%) 303 (7.0%)
Year of Due Date .01
 1997–1999 280 (18.2%) 839 (19.4%)
 2000–2001 348 (22.6%) 853 (19.8%)
 2002–2003 250 (16.3%) 855 (19.8%)
 2004–2005 346 (22.5%) 894 (20.7%)
 2006–2007 310 (20.2%) 872 (20.2%)
Infant Characteristics
Preterm Birth (<37 weeks) < .001
 Yes 375 (24.4%) 407 (9.4%)
 No 1141 (74.2%) 3,906 (90.5%)
Low Birth Weight (<2,500 g) < .001
 Yes 380 (24.7%) 241 (5.6%)
 No 1,137 (74.0%) 4,055 (94.0%)
Family History of Hypospadiasd < .001
 Yes 74 (4.8%) 9 (0.2%)
 No 1463 (95.2%) 4305 (99.8%)
a
P values were calculated by Pearson’s chi-square test.
b
Any time 1 month preconception through month 3 postconception.
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c
Any time 1 month preconception through month 4 postconception.
d
Family history of hypospadias in a first degree relative (father or full sibling) or mother’s previous pregnancy.
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Table 2
Association of Isolated Second- or Third-Degree Hypospadias with Periconceptional Maternal Medication 
Usea, National Birth Defects Prevention Study, October 1997 to December 2007.




OR (95% CI) Adjusted ORb (95% 
CI)
Antihistamines, First Generation
 Chlorpheniramine 37 78 1.4 (0.9, 2.0) 1.4 (0.6, 2.1)
 Diphenhydramine 38 99 1.1 (0.7, 1.6) 1.0 (0. 7, 1.5)
 Doxylamine succinate 27 68 1.1 (0.7, 1.8) 1.0 (0.6, 1.6)
 Promethazine 46 148 0.9 (0.6, 1.2) 0.8 (0. 6, 1.1)
Antihistamines, Second Generation
 Cetirizine HCl 21 46 1.3 (0.8, 2.2) 1.0 (0.6, 1.7)
 Fexofenadine HCl 22 39 1.6 (0.9, 2.7) 1.1 (0.7, 2.0)
 Loratadine 46 98 1.3 (0.9, 1.9) 1.1 (0.8, 1.6)
Antibiotics
 Amoxicillin trihydrate 85 233 1.0 (0.8, 1.3) 1.0 (0.8, 1.3)
 Azithromycin 19 70 0.8 (0.5, 1.3) 0.6 (0.4, 1.1)
 Cephalexin 10 34 0.8 (0.4, 1.7) 0.9 (0.4, 1.8)
 Nitrofurantoin 28 68 1.2 (0.8, 1.8) 1.3 (0.8, 2.1)
 Sulfamethoxazole 15 38 1.1 (0.6, 2.0) 1.1 (0.6, 2.0)
 Trimethoprim 15 38 1.1 (0.6, 2.0) 1.1 (0.6, 2.0)
Alpha/Beta Agonists
 Phenylpropanolamine 11 14 2.2 (1.0, 4.9) 2.0 (0.9, 4.8)
 Pseudoephedrine 148 392 1.1 (0.9, 1.3) 0.9 (0.7, 1.1)
Alpha-Adrenergic Agonists
 Phenylephrine 8 14 1.6 (0.7, 3.9) 1.6 (0.6, 4.1)
Analgesics
 Acetaminophen 956 2514 1.2 (1.1, 1.4) 1.0 (0.8, 1.1)
 Aspirin 93 187 1.4 (1.1, 1.8) 1.3 (0.9, 1.7)
 Codeine 14 42 0.9 (0.5, 1.7) 0.9 (0.4, 1.6)
 Ibuprofen 423 945 1.4 (1.2, 1.6) 1.2 (1.0, 1.3)
 Meperidine HCl 9 21 1.2 (0.6, 2.6) 1.2 (0.5, 2.6)
 Naproxen sodium 77 179 1.2 (0.9, 1.6) 1.0 (0.7, 1.3)
 Oxycodone 12 21 1.6 (0.8, 3.3) 1.0 (0.5, 2.3)
Antidepressants
 Bupropion HCl 12 26 1.3 (0.7, 2.6) 1.3 (0.7, 2.7)
 Fluoxetine HCl 13 42 0.9 (0.5, 1.6) 0.9 (0.5, 1.7)
 Paroxetine 9 29 0.9 (0.4, 1.9) 1.0 (0.5, 2.2)
 Sertraline HCl 22 48 1.3 (0.8, 2.2) 1.2 (0.7, 2.1)
 Venlafaxine 9 11 2.3 (1.0, 5.6) 2.4 (1.0, 6.0)
Antidiabetic Agents
 Insulin 12 19 1.8 (0.9, 3.7) 2.1 (0.9, 4.7)
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OR (95% CI) Adjusted ORb (95% 
CI)
 Metformin 7 13 1.5 (0.6, 3.8) 0.8 (0.3, 2.2)
Barbiturates
 Butalbital 8 8 2.8 (1.1, 7.5) 2.1 (0.7, 5.8)
Beta2-Adrenergic Agonists
 Albuterol sulfate 49 122 1.1 (0.8, 1.6) 1.1 (0.8, 1.6)
 Salmeterol xinafoate 12 20 1.7 (0.8, 3.5) 1.7 (0.8, 3.6)
Cardiovascular Agents
 Atenolol 5 10 1.4 (0.5, 4.1) 1.0 (0.3, 3.3)
 Labetalol 9 6 4.2 (1.5, 11.9) 2.6 (0.9, 7.7)
 Methyldopa 9 21 1.2 (0.6, 2.6) 1.1 (0.4, 2.5)
CNS Stimulants
 Caffeine 27 52 1.5 (0.9, 2.4) 1.1 (0.7, 1.8)
Fertility Agents
 Progesterone only* 46 71 1.8 (1.3, 2.7) 1.1 (0.7, 1.7)
 Clomiphene only 38 43 2.5 (1.6, 3.9) 1.9 (1.2, 3.0)
 FSH+HCG+LEU+PRO 17 11 4.4 (2.1, 9.4) 2.2 (1.0, 4.8)
 Clomiphene+PRO 10 10 2.8 (1.2, 6.8) 2.0 (0.8, 5.0)
 FSH+HCG+PRO 10 7 4.0 (1.5, 10.6) 1.7 (0.6, 4.7)
 FSH+PRO 7 6 3.3 (1.1, 9.8) 1.7 (0.5, 5.4)
GI, Antiemetics
 Ondansetron HCl 23 45 1.4 (0.9, 2.4) 1.0 (0.6, 1.7)
GI, Antiflatulants
 Simethicone 12 33 1.0 (0.5, 2.0) 0.7 (0.3, 1.4)
GI, Antiulcer Agents and Acid Suppressants
 Lansoprazole 6 6 2.8 (0.9, 8.7) 2.8 (0.8, 9.8)
 Omeprazole 5 5 2.8 (0.8, 9.8) 2.9 (0.7, 11.3)
 Ranitidine HCl 11 27 1.2 (0.6, 2.3) 0.9 (0.4, 1.9)
GI, Digestants
 Betaine 5 20 0.7 (0.3, 1.9) 0.7 (0.2, 1.8)
GI, Prokinetic Agents
 Metoclopramide 10 21 1.3 (0.6, 2.9) 1.0 (0.5, 2.3)
Herbals
 Alfalfa 7 22 0.9 (0.4, 2.1) 0.7 (0.3, 1.6)
 Allium sativum, herb 9 25 1.0 (0.5, 2.2) 0.9 (0.4, 2.1)
 Angelica polymorpha 8 22 1.0 (0.5, 2.3) 0.8 (0.3, 1.8)
 Barley grass 10 10 2.8 (1.2, 6.8) 2.1 (0.8, 5.4)
 Bee pollen 11 29 1.1 (0.5, 2.1) 1.1 (0.5, 2.2)
 Bioflavonoid 19 47 1.1 (0.7, 2.0) 0.8 (0.5, 1.5)
Compound
 Cranberry Concentrate 6 9 1.9 (0.7, 5.3) 1.6 (0.6, 4.6)
 Echinacea 11 22 1.4 (0.7, 2.9) 1.2 (0.6, 2.7)













Lind et al. Page 18




OR (95% CI) Adjusted ORb (95% 
CI)
 Ephedra 8 28 0.8 (0.4, 1.8) 1.0 (0. 5, 2.4)
 Ginger 17 43 1.1 (0.6, 2.0) 1.0 (0.6, 1.9)
 Ginkgo biloba extract 8 13 1.7 (0.7, 4.2) 1.6 (0.6, 4.4)
 Ginseng 10 20 1.4 (0.7, 3.0) 1.4 (0.6, 3.2)
 Herbal tea 17 35 1.4 (0.8, 2.5) 1.8 (1.0, 3.5)
 Hesperidin Complex 5 6 2.4 (0.7, 7.7) 2.1 (0.6, 7.1)
 Hydrastis canadensis 6 12 1.4 (0.5, 3.8) 1.6 (0.6, 4.5)
 Hypericum perforatum 5 6 2.4 (0.7, 7.7) 1.7 (0.5, 5.9)
 Peppermint 5 13 1.1 (0.4, 3.0) 0.8 (0.3, 2.3)
 Raspberry leaf 18 33 1.5 (0.9, 2.7) 0.9 (0.5, 1.8)
 Rutin 9 30 0.8 (0.4, 1.8) 0.7 (0.3, 1.4)
 Sarsaparilla root 5 8 1.8 (0.6, 5.4) 2.3 (0.7, 7.6)
 Siberian ginseng 5 13 1.1 (0.4, 3.0) 1.2 (0.4, 3.5)
 Spirulina 11 26 1.2 (0.6, 2.4) 0.9 (0.4, 1.8)
 Thea sinesis 12 32 1.1 (0.5, 2.1) 0.9 (0.4, 1.8)
 Vitis vinifera 8 10 2.3 (0.9, 5.7) 1.9 (0.7, 5.3)
Hormonal Contraceptive Medications
 Estrogen+Progestinc,d 70 212 1.0 (0.6, 1.5) 1.0 (0.7, 1.5)
 Progestin onlyc,e 29 95 1.1 (0.8, 1.5) 1.9 (1.1, 3.2)
Respiratory Agents
 Dextromethorphan 51 113 1.3 (0.9, 1.8) 1.1 (0.7, 1.5)
 Guaifenesin 41 120 1.0 (0.7, 1.4) 0.8 (0.6, 1.2)
Steroids, Glucocorticoids
 Budesonide 6 8 2.1 (0.7, 6.1) 1.2 (0.4, 3.7)
 Fluticasone 21 39 1.5 (0.9, 2.6) 1.1 (0.6, 2.0)
 Prednisone 5 15 0.9 (0.3, 2.6) 0.6 (0.2, 1.7)
 Triamcinolone 5 9 1.6 (0.5, 4.7) 1.5 (0.5, 4.9)
Thyroid and Antithyroid Agents
 Levothyroxine sodium 45 71 1.8 (1.2, 2.7) 1.3 (0.9, 2.0)
 Potassium iodide 67 176 1.1 (0.8, 1.4) 0.8 (0.6, 1.1)
Miscellaneous Therapeutic Agents
 Lactobacillus acidophilus 5 14 1.0 (0.4, 2.8) 0.7 (0.2, 2.0)
 Glucosamine 6 3 --- ---
 Potassium clavulanate 8 18 1.3 (0.5, 2.9) 1.2 (0.5, 2.8)
 Royal jelly 10 31 0.9 (0.4, 1.9) 0.8 (0.4, 1.7)
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index.
a
Medication exposure is reported for the period from 1 month before to 4 months after conception.
b
Odds ratios are adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, previous live births, sub-fertility, study site, and year of 
due date. Fertility agents other than progesterone alone were not adjusted for sub-fertility.
*
Progesterone use was reported either for subfertility or for pregnancy complications.
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c
Progestin and estrogen compound exposures are in response to questions during the maternal interview about oral contraceptives only and include 
only exposures through month 3 postconception.
d
Progestin and estrogen compounds include combinations of the following estrogen compounds: ethinyl estradiol, estradiol cypionate, and NOS-
estrogen; and the following progestin compounds: desogestrel, drosperinone, etonogestrel, levonorgestrel, medroxyprogesterone, norelgestromin, 
norethnidrone, norgestimate, and progestin NOS
e
Progestin only medications include levonorgestrel, medroxyprogesterone, norethindrone, and progestin NOS
--- Odds ratios were not estimated for medication components with fewer than 5 exposed controls.
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Table 3
Association of Isolated Second- or Third-Degree Hypospadias with Maternal Periconceptional Use of Specific 
Medications, Excluding Infants with a Positive First Degree Family History, National Birth Defects 
Prevention Study, October 1997 to December 2007.a,b




aORc (95% CI) Sub-
Analysis
aOR (95% CI) Primary 
Analysis
Acetaminophen 895 2507 0.9 (0.8, 1.1) 1.0 (0.8, 1.1)
Aspirin 90 186 1.3 (1.0, 1.7) 1.3 (0.9, 1.7)
Azithromycin 19 70 0.7 (0.4, 1.1) 0.6 (0.4, 1.1)
Barley grass 8 10 1.7 (0.6, 4.4) 2.1 (0.8, 5.4)
Butalbital 8 8 2.2 (0.8, 6.1) 2.1 (0.7, 5.8)
Progesterone onlyd 42 71 1.1 (0.7, 1.6) 1.1 (0.7, 1.7)
Clomiphene only 35 43 1.7 (1.1, 2.8) 1.9 (1.2, 3.0)
FSH+HCG+LEU+PRO 17 11 2.3 (1.0, 5.0) 2.2 (1.0, 4.8)
CLO+PRO 10 10 2.1 (0.8, 5.3) 2.0 (0.8, 5.0)
FSH+HCG+PRO 10 7 1.8 (0.7, 5.0) 1.7 (0.6, 4.7)
FSH+PRO 6 6 1.6 (0.5, 5.4) 1.7 (0.5, 5.4)
Herbal tea 16 35 1.8 (0.9, 3.5) 1.8 (1.0, 3.5)
Ibuprofen 403 942 1.2 (1.0, 1.4) 1.2 (1.0, 1.3)
Labetalol 9 6 2.7 (0.9, 8.0) 2.6 (0.9, 7.7)
Levothyroxine sodium 43 71 1.3 (0.9, 2.0) 1.3 (0.9, 2.0)
Phenylpropanolamine 10 14 1.9 (0.8, 4.7) 2.0 (0.9, 4.8)
Progestin-only oral contraceptives 29 95 2.0 (1.2, 3.4) 1.9 (1.1, 3.2)
Venlafaxine 9 11 2.5 (1.0, 6.3) 2.4 (1.0, 6.0)
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval
a
Medication exposure is reported for the period from 1 month before to 4 months after conception.
b
Family history of hypospadias in a first degree relative (father or full sibling) or mother’s previous pregnancy.
c
Odds ratios were adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, previous live births, sub-fertility, study site, and year of 
due date. Fertility agents were not adjusted for sub-fertility.
d
Progesterone use was reported either for subfertility or for pregnancy complications.
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Table 4
Association of Isolated Second- or Third-Degree Hypospadias with Maternal Periconceptional Use of Specific 
Medications, Excluding Low Birth Weight Infants and Multiple Births, National Birth Defects Prevention 
Study, October 1997 to December 2007.a




aORb (95% CI) Sub-
Analysis
aOR (95% CI) 
Primary Analysis
Acetaminophen 701 2318 1.0 (0.8, 1.1) 1.0 (0.8, 1.1)
Aspirin 61 164 1.2 (0.9, 1.7) 1.3 (0.9, 1.7)
Azithromycin 18 66 0.7 (0.4, 1.3) 0.6 (0.4, 1.1)
Barley grass 6 10 1.7 (0.6, 4.8) 2.1 (0.8, 5.4)
Butalbital 5 8 1.5 (0.5, 4.8) 2.1 (0.7, 5.8)
Progesterone onlyc 33 59 1.3 (0.8, 2.1) 1.1 (0.7, 1.7)
Clomiphene only 20 34 1.6 (0.9, 2.9) 1.9 (1.2, 3.0)
FSH+HCG+LEU+PRO 3 4 --- 2.2 (1.0, 4.8)
CLO+PRO 6 8 1.6 (0.5, 4.9) 2.0 (0.8, 5.0)
FSH+HCG+PRO 5 3 --- 1.7 (0.6, 4.7)
FSH+PRO 2 5 --- 1.7 (0.5, 5.4)
Herbal tea 10 32 1.7 (0.8, 3.7) 1.8 (1.0, 3.5)
Ibuprofen 309 873 1.2 (1.0, 1.4) 1.2 (1.0, 1.3)
Labetalol 4 5 --- 2.6 (0.9, 7.7)
Levothyroxine sodium 31 61 1.4 (0.9, 2.2) 1.3 (0.9, 2.0)
Phenylpropanolamine 7 13 2.0 (0.7, 5.4) 2.0 (0.9, 4.8)
Progestin-only oral contraceptives 16 89 1.3 (0.7, 2.6) 1.9 (1.1, 3.2)
Venlafaxine 9 9 3. 7 (1.4, 9.7) 2.4 (1.0, 6.0)
Abbreviations: OR, odds ratio; CI, confidence interval.
a
Medication exposure is reported for the period from 1 month before to 4 months after conception.
b
Odds ratios are adjusted for maternal age, race/ethnicity, education, pre-pregnancy BMI, previous live births, sub-fertility, study site, and year of 
due date. Fertility agents were not adjusted for sub-fertility.
--- Odds ratios were not estimated for medication components with fewer than 5 exposed cases.
c
Progesterone use was reported either for subfertility or for pregnancy complications
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